Thomas J. Galloway, MD

Thomas Galloway, MD
​​
This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings
Request an Appointment

Clinical Locations

Professor, Department of Radiation Oncology

Chief, Division of Head and Neck Radiation Oncology

Medical Director, Clinical Research

 

Treatment Focus

  • Intensity modulated radiation therapy
  • Stereotactic body radiation therapy
  • Modulated electron beam therapy
  • Interstitial brachytherapy
  • Rotational arc therapy

Key Awards

2023 top doctors
Radiation Oncology
  • ARRO Educator of the year, Fox Chase Cancer Center 2013
  • Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013

Treatment Philosophy

I joined Fox Chase after completing my residency at the University of Florida in 2010. I specialize in treating cancers of the head and neck and skin cancer.

Cancer is a complicated, confusing diagnosis. Cancers of the head and neck are particularly challenging because they occur in areas that can affect our ability to perform some of our most basic functions: breathing, speaking, and eating.

I came to Fox Chase because I believe that the best way to cure these difficult cancers while maintaining quality of life is through a multi-disciplinary approach. Some cancers are cured with radiation alone, some need the assistance of both surgery and chemotherapy, and some are cured without radiation. The team approach at Fox Chase ensures that many different disciplines are working together to decide the best treatment for your unique case with one unifying goal: curing your cancer while avoiding unnecessary toxicity

Educational Background

  • MD, University of Florida, Gainesville, FL, 2005
  • BS, Chemistry, University of Florida, Gainesville, FL, 2001

Certifications

  • American Board of Radiology
  • Radiation Oncology

Memberships

  • American Society of Therapeutic Radiology (ASTRO)
  • Radiation Therapy Oncology Group (RTOG)
  • Institutional Principal Investigator for Fox Chase Cancer Center (Institution 2212) July 2013 - Present
  • American Radium Society (ARS)
  • Radiological Society of North America (RSNA)
  • American College of Radiology (ACR)
  • Eastern Cooperative Oncology Group (ECOG)

Honors & Awards

  • ARRO Educator of the year, Fox Chase Cancer Center 2013
  • Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013

Tierra Ryan

  • Lymphoma

At 31, Tierra Ryan was a young professional woman, working as a pharmacist and a medical writer for a large pharmaceutical company, when she was shocked to learn she was diagnosed with Hodgkin's lymphoma. Fox Chase Cancer Center was one of two hospitals her doctor recommended. Tierra underwent chemotherapy and radiation therapy at Fox Chase, and in November 2014 was placed on surveillance because her cancer was in remission. Today, she still works in the pharmaceutical industry, but as a medical science liaison focusing on oncology. "I’m truly thankful to the doctors and staff at Fox Chase because they saved my life," Tierra said. "Because of them, I have a long life ahead of me."

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

VIEW PATIENT STORY

Research Interests

  • Head and neck cancer
  • Head and neck cancer survivorship
  • Skin Cancer (both melanoma and non-melanoma)
  • Merkel Cell Carcinoma Radiation target delineation
  • Pre-treatment imaging evaluation beyond the diagnosis
  • Impact of time to treatment in the curative management of head and neck cancer

Selected Publications

Ebersole B., McCarroll L., Ridge J.A., Liu J.C., Bauman J., Donnelly S., Galloway T.J., Identification and management of late dysfunction in survivors of head and neck cancer: Implementation and outcomes of an interdisciplinary quality of life (iqol) clinic. Head Neck. 43(7): 2124-2135, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33749012.

Lee C.T., Galloway T.J., Pathogenesis and amelioration of radiation-induced oral mucositis. Curr Treat Options Oncol. 23(3): 311-324, 2022. PMC8931694. https://www.ncbi.nlm.nih.gov/pubmed/35244887.

Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. The Survival Impact of Increasing Time to Treatment Initiation for Patients with Head and Neck Cancer in the United States. Accepted for publication in Journal of Clinical Oncology PubMed

Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, Galloway TJ. Pre-Treatment Tumor-Specific Growth Rate as a Temporal Biomarker that Predicts Treatment Failure and Improves Risk Stratification for Oropharyngeal Cancer. Accepted for publication in Oral Oncology PubMed

Lango MN, Galloway TJ, Mehra R, Ebersole B, Liu JC, Burtness B, Moran K, Ridge JA.  Impact of baseline dysphagia on acute feeding tube placement in head and neck cancer patients undergoing definitive radiation.  Epub ahead of print in Head and Neck PubMed

Galloway TJ, Ridge JA.  Management of squamous cancer metastatic to cervical nodes with unknown primary.  Epub ahead of print in Journal of Clinical Oncology PubMed

Galloway TJ, Wirth L, Colevas D, Gilbert J, Bauman J, Saba N, Raben D, Mehra R, Burtness B, Jimeno A. A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma (Clinical Cancer Research 2015; 21(7) 1566-1573). PubMed

Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. Increasing time to treatment initiation for squamous cell carcinoma of the head and neck: An analysis of the National Cancer Database. (Cancer 2015; 121(8) 1204-1213). PubMed

Nguyen-Tan PF, Zhang QE, Ang KK, Wheeler RH, Weber RS, Rosenthal DI, Bahary JP, Kim H, Silverman C, Raben A, Galloway T, Vigneault E, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. A Randomized Phase III Trial to Test Accelerated versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Long Term Report of Efficacy and Toxicity. (Journal of Clinical Oncology 2014; 32(34) 3858-3867 

Lango MN, Egleston B, Fang CY, Burtness B, Galloway T, Liu JC, Mehra R, Ebersole B, Moran KM, Ridge JA. Baseline Health Perceptions, weight-loss and survival in head and neck cancer. (Cancer 2014; 120(6):840-7... Expand

Additional Publications

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...
​​